Overall response rate · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor probably leads to higher overall response rate compared with any cytotoxic chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).
1 finding from 1 review
Intervention not reported
Overall survival (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival (Duration of (high certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 1‐year survival rate  · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 1‐year survival rate  (low certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 2‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 2‐year survival rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 3‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 3‐year survival rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall survival: 5‐year survival rate · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in overall survival: 5‐year survival rate (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: any (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in adverse events: any (Duration of (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: severe, grade > 2 (Duration of · stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
The intervention showed no clear difference in adverse events: severe, grade > 2 (Duration of (low certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).
1 finding from 1 review
Overall response rate (ORR), · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
QoL · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (OSR) · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review